JamesPDeanMDPhD
Oncology • South San Francisco, CAGenitourinary Oncology, Hematologic Oncology
Executive Medical Director, Oncology Development, AbbVie (Pharmacyclics)
Dr. Dean is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1000 Gateway Blvd
South San Francisco, CA 94080Phone+1 650-788-7321
Summary
- Dr. James Dean is an Oncologist specializing in Drug Development in Hematologic Oncology. His education includes a fellowship in Medical Oncology at Fred Hutchinson Cancer Research Center/University of Washington, residency in Internal Medicine at SUNY Stony Brook, and a MD, PhD from the University of Iowa. Professionally, he currently serves as Executive Medical Director at AbbVie (Pharmacyclics). He has held several significant roles in his career, including positions at CTI Biopharma Corp, Seattle Genetics, Inc, UW Medicine/University of Washington Medical Center, and Fred Hutchinson Cancer Research Center. He has expertise in conditions such as hematologic oncology (CLL, DLBCL, MCL, FL, myelofibrosis), prostate cancer, and bladder cancer. He has also contributed significantly to medical literature, including extensive work in chronic lymphocytic leukemia treatment.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2003 - 2006
Stony Brook Medicine/University HospitalResidency, Internal Medicine, 2000 - 2003
University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 2000
Certifications & Licensure
WA State Medical License 2003 - 2026
Publications & Presentations
PubMed
- 302 citationsFinal analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphomaTalha Munir, Jennifer R. Brown, Susan O'Brien, Jacqueline C. Barrientos, Paul M. Barr
American Journal of Hematology. 2019-12-01 - 6 citationsAbsence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax.Nitin Jain, Lisa J Croner, John N Allan, Tanya Siddiqi, Alessandra Tedeschi
Clinical Cancer Research. 2024-02-01 - 94 citationsFixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.Constantine S Tam, John N Allan, Tanya Siddiqi, Thomas J Kipps, Ryan Jacobs
Blood. 2022-06-02
Professional Memberships
- Member
- Member
- European Research Initiative on CLL (ERIC)Member
- Society of Hematologic Oncology.Member
- European Hematology AssociationMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
